Cancer reports最新文献_第3页

Risk Factors and Clinical Outcomes of Recurrence in Adult Ovarian Granulosa Cell Tumors 成人卵巢颗粒细胞瘤复发的风险因素和临床结果

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-10-25 DOI: 10.1002/cnr2.70036

Mansoureh Golmohammadi Tavallaee, Malihe Hasanzadeh Mofrad, Zohreh Yousefi, Mansoureh Mottaghi, Fatemeh Homaei Shandiz, Behrouz Davachi, Bahram Hamidi, Marjaneh Farazestanian, Fahimeh Afzaljavan

Purpose

Granulosa cell tumors (GCTs) of the ovary are rare but clinically significant malignancies. Despite advances in treatment, recurrence has remained a substantial challenge. This study aimed to identify clinical outcomes and potential prognostic risk factors for recurrence in patients diagnosed with GCTs.

Methods

In a retrospective cohort study, the ovarian cancer database of the gynecological tertiary referral cancer center, Mashhad University of Medical Sciences, Mashhad, Iran, was searched from August 2012 to August 2023 to find GCT cases. Demographic, clinical, pathological, intervention-related factors, follow-up, and survival findings were meticulously collected. Data were analyzed using SPSS v 23.

Results

Ninety-two patients with GCTs, including 86 AGCT and 6 JGCT subjects, were identified. Based on further analysis of AGCT patients, most patients were ages under 50 (58.1%), clinically presented pain (32.6%), and abnormal uterine bleeding (27.9%) as the most frequent symptoms. Stages IA (64.0%) and IC (20.9%) were common. Five-year overall and progression-free survival were 98.2% and 90.8%, respectively. With a median follow-up time of 72 (0.0–180) months, disease recurrence was observed in 19 patients (23.9%), and five patients (5.4%) died of the disease. Stage IV was a hazard factor of recurrence (HR = 7.62, 95%CI (1.89–30.63); p = 0.004).

Conclusions

The present study provides valuable insights into the outcomes and potential risk factors for recurrence in ovarian AGCTs. It duplicates the importance of stage in the prognosis of AGCT patients and highlights the safety of fertility-sparing surgery in stage I and the lack of need to administer chemotherapy in stage IC.

目的：卵巢颗粒细胞瘤（GCT）是一种罕见但临床意义重大的恶性肿瘤。尽管在治疗方面取得了进展，但复发仍然是一个巨大的挑战。本研究旨在确定确诊为GCTs患者的临床结果和潜在的复发预后风险因素：在一项回顾性队列研究中，研究人员检索了伊朗马什哈德市马什哈德医科大学妇科三级癌症转诊中心的卵巢癌数据库，寻找 2012 年 8 月至 2023 年 8 月期间的 GCT 病例。仔细收集了人口统计学、临床、病理学、干预相关因素、随访和生存结果。数据采用 SPSS v 23 进行分析：结果：共发现 92 例 GCT 患者，包括 86 例 AGCT 和 6 例 JGCT 受试者。根据对 AGCT 患者的进一步分析，大多数患者的年龄在 50 岁以下（58.1%），临床表现以疼痛（32.6%）和异常子宫出血（27.9%）为最常见症状。IA期（64.0%）和IC期（20.9%）很常见。五年总生存率和无进展生存率分别为98.2%和90.8%。中位随访时间为72（0.0-180）个月，19名患者（23.9%）出现疾病复发，5名患者（5.4%）死于疾病。IV期是复发的危险因素（HR = 7.62，95%CI (1.89-30.63)；P = 0.004）：本研究为卵巢AGCT的结果和潜在复发风险因素提供了宝贵的见解。它重复了分期对 AGCT 患者预后的重要性，并强调了 I 期保胎手术的安全性和 IC 期化疗的必要性。

{"title":"Risk Factors and Clinical Outcomes of Recurrence in Adult Ovarian Granulosa Cell Tumors","authors":"Mansoureh Golmohammadi Tavallaee, Malihe Hasanzadeh Mofrad, Zohreh Yousefi, Mansoureh Mottaghi, Fatemeh Homaei Shandiz, Behrouz Davachi, Bahram Hamidi, Marjaneh Farazestanian, Fahimeh Afzaljavan","doi":"10.1002/cnr2.70036","DOIUrl":"10.1002/cnr2.70036","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>Granulosa cell tumors (GCTs) of the ovary are rare but clinically significant malignancies. Despite advances in treatment, recurrence has remained a substantial challenge. This study aimed to identify clinical outcomes and potential prognostic risk factors for recurrence in patients diagnosed with GCTs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In a retrospective cohort study, the ovarian cancer database of the gynecological tertiary referral cancer center, Mashhad University of Medical Sciences, Mashhad, Iran, was searched from August 2012 to August 2023 to find GCT cases. Demographic, clinical, pathological, intervention-related factors, follow-up, and survival findings were meticulously collected. Data were analyzed using SPSS v 23.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ninety-two patients with GCTs, including 86 AGCT and 6 JGCT subjects, were identified. Based on further analysis of AGCT patients, most patients were ages under 50 (58.1%), clinically presented pain (32.6%), and abnormal uterine bleeding (27.9%) as the most frequent symptoms. Stages IA (64.0%) and IC (20.9%) were common. Five-year overall and progression-free survival were 98.2% and 90.8%, respectively. With a median follow-up time of 72 (0.0–180) months, disease recurrence was observed in 19 patients (23.9%), and five patients (5.4%) died of the disease. Stage IV was a hazard factor of recurrence (HR = 7.62, 95%CI (1.89–30.63); <i>p</i> = 0.004).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The present study provides valuable insights into the outcomes and potential risk factors for recurrence in ovarian AGCTs. It duplicates the importance of stage in the prognosis of AGCT patients and highlights the safety of fertility-sparing surgery in stage I and the lack of need to administer chemotherapy in stage IC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 10","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Impact of the COVID-19 Pandemic on Mental Health and Cognitive Function in Patients With Cancer: A Systematic Literature Review COVID-19 大流行对癌症患者心理健康和认知功能的影响：系统性文献综述

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-10-23 DOI: 10.1002/cnr2.70008

Sílvia Almeida, Diana Frasquilho, M. Teresa Cordeiro, Teresa Neto, Berta Sousa, Fátima Cardoso, Albino J. Oliveira-Maia

Background

The COVID-19 pandeminc has had widespread impacts, but its specific effects on mental health and cognitive function in patients with cancer remain under-explored.

Recent Findings

Data from the general population has suggested that mental health problems were frequent during the pandemic, namely during the initial stage of the outbreak. For patients with cancer, a systematic review and meta-analysis of data published until January 2021 also showed elevated prevalence of depression and anxiety, and suggested that anxiety was more frequent than in health workers and healthy controls.

Objective

This systematic review aimed to synthesize existing evidence on the impact of the COVID-19 pandemic on mental health and cognitive function in patients with cancer.

Methods

Studies were identified through systematic search of three electronic bibliographic databases (PubMed, Web of Science, and EBSCOHOST) with adapted search strings. We included only peer-reviewed, nonqualitative, original research papers, published between 2019 and 2022, and reporting on mental health and/or cognition outcomes during the COVID-19 pandemic in adult patients with cancer.

Results

Of 3260 papers identified, 121 full text articles were retrieved and 71 met inclusion criteria. We found that patients with cancer reported high levels of psychological distress, anxiety and depression, as well as cognitive complaints during the pandemic. However, studies were not consistent in identifying these symptoms as effects of the pandemic specific for this population. In fact, longitudinal studies did not find consistent differences between pre- and post-pandemic periods and, globally, patients with cancer did not report increased severity of these mental health symptoms in relation to the general population.

Conclusion

Overall, while the COVID-19 pandemic may have raised mental health challenges for patients with cancer, the diagnosis of cancer and associated treatments seemed to remain the main source of concern for these patients.

背景：COVID-19 大流行产生了广泛的影响，但其对癌症患者精神健康和认知功能的具体影响仍未得到充分探讨：最近的研究结果：来自普通人群的数据表明，大流行期间，即疫情爆发初期，精神健康问题频发。就癌症患者而言，一项对截至 2021 年 1 月发表的数据进行的系统综述和荟萃分析也显示，抑郁和焦虑的患病率升高，而且焦虑的发生率高于医务工作者和健康对照组：本系统综述旨在综合现有证据，说明 COVID-19 大流行对癌症患者心理健康和认知功能的影响：通过对三个电子文献数据库（PubMed、Web of Science 和 EBSCOHOST）进行系统检索，并调整检索字符串，确定了相关研究。我们只收录了经同行评审的、非定性的、原创性研究论文，这些论文发表于 2019 年至 2022 年之间，报告了在 COVID-19 大流行期间成年癌症患者的心理健康和/或认知结果：在确定的 3260 篇论文中，检索到 121 篇全文，其中 71 篇符合纳入标准。我们发现，在大流行期间，癌症患者报告的心理困扰、焦虑和抑郁以及认知抱怨的程度很高。然而，这些研究并没有一致地将这些症状视为大流行对这一人群的特定影响。事实上，纵向研究并没有发现大流行前后的一致差异，而且从全球范围来看，癌症患者报告的这些心理健康症状的严重程度并没有高于普通人群：总之，虽然 COVID-19 大流行可能会给癌症患者的心理健康带来挑战，但癌症诊断和相关治疗似乎仍是这些患者的主要担忧。

{"title":"The Impact of the COVID-19 Pandemic on Mental Health and Cognitive Function in Patients With Cancer: A Systematic Literature Review","authors":"Sílvia Almeida, Diana Frasquilho, M. Teresa Cordeiro, Teresa Neto, Berta Sousa, Fátima Cardoso, Albino J. Oliveira-Maia","doi":"10.1002/cnr2.70008","DOIUrl":"10.1002/cnr2.70008","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The COVID-19 pandeminc has had widespread impacts, but its specific effects on mental health and cognitive function in patients with cancer remain under-explored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>Data from the general population has suggested that mental health problems were frequent during the pandemic, namely during the initial stage of the outbreak. For patients with cancer, a systematic review and meta-analysis of data published until January 2021 also showed elevated prevalence of depression and anxiety, and suggested that anxiety was more frequent than in health workers and healthy controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This systematic review aimed to synthesize existing evidence on the impact of the COVID-19 pandemic on mental health and cognitive function in patients with cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Studies were identified through systematic search of three electronic bibliographic databases (PubMed, Web of Science, and EBSCOHOST) with adapted search strings. We included only peer-reviewed, nonqualitative, original research papers, published between 2019 and 2022, and reporting on mental health and/or cognition outcomes during the COVID-19 pandemic in adult patients with cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 3260 papers identified, 121 full text articles were retrieved and 71 met inclusion criteria. We found that patients with cancer reported high levels of psychological distress, anxiety and depression, as well as cognitive complaints during the pandemic. However, studies were not consistent in identifying these symptoms as effects of the pandemic specific for this population. In fact, longitudinal studies did not find consistent differences between pre- and post-pandemic periods and, globally, patients with cancer did not report increased severity of these mental health symptoms in relation to the general population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Overall, while the COVID-19 pandemic may have raised mental health challenges for patients with cancer, the diagnosis of cancer and associated treatments seemed to remain the main source of concern for these patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 10","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11498061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiomics Signatures Based on Computed Tomography for Noninvasive Prediction of CXCL10 Expression and Prognosis in Ovarian Cancer 基于计算机断层扫描的放射组学特征用于无创预测卵巢癌中 CXCL10 的表达和预后

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-10-23 DOI: 10.1002/cnr2.70030

Xiaohua Wang, Yuanyuan Xing, Xuan Zhou, Chunhui Wang, Shuyu Han, Sufen Zhao

Background

Ovarian cancer (OC) is an aggressive gynecological tumor usually diagnosed with malignant ascites and even observed widespread metastasis or distant spread.

Aims

We aimed to develop and identify radiomics models according to computed tomography (CT) for preoperative prediction of CXCL10 expression and prognosis in patients with OC.

Methods

Genomic data with CT images and corresponding clinicopathological parameters were extracted from The Cancer Imaging Archive (TCIA) and The Cancer Genome Atlas (TCGA). To analyze the prognosis, we carried out the univariate Cox regression analysis (UCRA), multivariate Cox regression analysis (MCRA), and Kaplan–Meier (KM) analysis. For the data reduction, logistic regression, operator regression, least absolute shrinkage selection, radiomic feature construction, and feature selection were utilized. The predictive performance of the radiomic signatures was assessed using the analyses of the receiver operating characteristic (ROC) curve, decision curve (DCA), and precision-recall (PR) curve. To evaluate the correlation between the radiomic score (Rad-score) and CXCL10 expression, the Wilcoxon rank-sum test was applied.

Results

Three radiomics models effectively predicted CXCL10 expression levels (AUC = 0.791, 0.748, and 0.718 for the set of training; AUC = 0.761, 0.746, and 0.701 for the set of validation). A higher Rad-score significantly correlated with upregulated CXCL10 expression.

Conclusion

CXCL10 expression can be predicted noninvasively and preoperatively via radiomic signatures based on contrast-enhanced CT images.

背景：卵巢癌（OC）是一种侵袭性妇科肿瘤：卵巢癌（OC）是一种侵袭性妇科肿瘤，通常以恶性腹水确诊，甚至可观察到广泛转移或远处扩散。目的：我们旨在根据计算机断层扫描（CT）开发和确定放射组学模型，用于术前预测OC患者的CXCL10表达和预后：从癌症影像档案（TCIA）和癌症基因组图谱（TCGA）中提取了带有CT图像和相应临床病理参数的基因组数据。为了分析预后，我们进行了单变量 Cox 回归分析（UCRA）、多变量 Cox 回归分析（MCRA）和 Kaplan-Meier 分析（KM）。在数据缩减方面，采用了逻辑回归、算子回归、最小绝对缩减选择、放射特征构建和特征选择等方法。利用接收者操作特征曲线（ROC）、决策曲线（DCA）和精确度-召回（PR）曲线分析评估了放射学特征的预测性能。为了评估放射组学评分（Rad-score）与CXCL10表达之间的相关性，采用了Wilcoxon秩和检验：结果：三种放射组学模型能有效预测 CXCL10 的表达水平（训练集的 AUC = 0.791、0.748 和 0.718；验证集的 AUC = 0.761、0.746 和 0.701）。较高的 Rad 评分与上调的 CXCL10 表达明显相关：结论：CXCL10的表达可以通过基于对比增强CT图像的放射学特征进行无创和术前预测。

{"title":"Radiomics Signatures Based on Computed Tomography for Noninvasive Prediction of CXCL10 Expression and Prognosis in Ovarian Cancer","authors":"Xiaohua Wang, Yuanyuan Xing, Xuan Zhou, Chunhui Wang, Shuyu Han, Sufen Zhao","doi":"10.1002/cnr2.70030","DOIUrl":"10.1002/cnr2.70030","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ovarian cancer (OC) is an aggressive gynecological tumor usually diagnosed with malignant ascites and even observed widespread metastasis or distant spread.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We aimed to develop and identify radiomics models according to computed tomography (CT) for preoperative prediction of <i>CXCL10</i> expression and prognosis in patients with OC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Genomic data with CT images and corresponding clinicopathological parameters were extracted from The Cancer Imaging Archive (TCIA) and The Cancer Genome Atlas (TCGA). To analyze the prognosis, we carried out the univariate Cox regression analysis (UCRA), multivariate Cox regression analysis (MCRA), and Kaplan–Meier (KM) analysis. For the data reduction, logistic regression, operator regression, least absolute shrinkage selection, radiomic feature construction, and feature selection were utilized. The predictive performance of the radiomic signatures was assessed using the analyses of the receiver operating characteristic (ROC) curve, decision curve (DCA), and precision-recall (PR) curve. To evaluate the correlation between the radiomic score (Rad-score) and <i>CXCL10</i> expression, the Wilcoxon rank-sum test was applied.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three radiomics models effectively predicted <i>CXCL10</i> expression levels (AUC = 0.791, 0.748, and 0.718 for the set of training; AUC = 0.761, 0.746, and 0.701 for the set of validation). A higher Rad-score significantly correlated with upregulated <i>CXCL10</i> expression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p><i>CXCL10</i> expression can be predicted noninvasively and preoperatively via radiomic signatures based on contrast-enhanced CT images.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 10","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Case of Epithelioid Angiosarcoma Diagnosed From Gross Examination of a Pulmonary Tumor Utilizing Imprint Cytology and Immunocytochemistry 一例利用印迹细胞学和免疫细胞化学从肺部肿瘤的大体检查中诊断出的上皮样血管肉瘤

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-10-23 DOI: 10.1002/cnr2.70014

Tatsuya Mori, Keishi Mizuguchi, Chie Shimaguchi, Kaori Sakano, Tsubasa Shimoda, Urara Okawa, Miyu Okuda, Mayo Usui, Hiroko Ikeda

Background

Angiosarcoma, a very rare malignant tumor constituting 2%–4% of soft tissue sarcomas, manifest in diverse organs including skin, soft tissues, and bones. Histologically, angiosarcoma presents a wide range of morphologies, with epithelioid angiosarcoma (EAS) resemblance to carcinoma. The difficulty arises from the shared epithelial-like morphology and expression of epithelial markers in immunohistochemistry.

Case

This study reports a case where EAS diagnosis was achieved through a combination of gross findings in a lung resection sample, imprint cytology, and immunocytochemistry. Imprint cytology revealed clusters of epithelioid cells, while immunocytochemistry showed positive results for CD31, ERG, Fli-1, and AE1/AE3, proving instrumental in diagnosing EAS. The described immunocytochemical protocol facilitates prompt diagnosis exclusively through cytology samples.

Conclusion

This report emphasizes the potential for diagnosing EAS using cytological specimens, which is especially useful in cases where obtaining tissue samples proves challenging.

背景：血管肉瘤是一种非常罕见的恶性肿瘤，占软组织肉瘤的 2%-4%，表现为皮肤、软组织和骨骼等多种器官。组织学上，血管肉瘤的形态多种多样，其中上皮样血管肉瘤（EAS）与癌相似。病例：本研究报告了一例通过肺部切除样本的大体检查结果、印迹细胞学和免疫细胞化学相结合确诊为上皮样血管肉瘤的病例。印迹细胞学显示有成群的上皮样细胞，而免疫细胞化学则显示 CD31、ERG、Fli-1 和 AE1/AE3 阳性，这有助于诊断 EAS。所述免疫细胞化学方案有助于仅通过细胞学样本进行及时诊断：本报告强调了利用细胞学标本诊断 EAS 的可能性，这在获取组织样本具有挑战性的病例中尤其有用。

{"title":"A Case of Epithelioid Angiosarcoma Diagnosed From Gross Examination of a Pulmonary Tumor Utilizing Imprint Cytology and Immunocytochemistry","authors":"Tatsuya Mori, Keishi Mizuguchi, Chie Shimaguchi, Kaori Sakano, Tsubasa Shimoda, Urara Okawa, Miyu Okuda, Mayo Usui, Hiroko Ikeda","doi":"10.1002/cnr2.70014","DOIUrl":"10.1002/cnr2.70014","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Angiosarcoma, a very rare malignant tumor constituting 2%–4% of soft tissue sarcomas, manifest in diverse organs including skin, soft tissues, and bones. Histologically, angiosarcoma presents a wide range of morphologies, with epithelioid angiosarcoma (EAS) resemblance to carcinoma. The difficulty arises from the shared epithelial-like morphology and expression of epithelial markers in immunohistochemistry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>This study reports a case where EAS diagnosis was achieved through a combination of gross findings in a lung resection sample, imprint cytology, and immunocytochemistry. Imprint cytology revealed clusters of epithelioid cells, while immunocytochemistry showed positive results for CD31, ERG, Fli-1, and AE1/AE3, proving instrumental in diagnosing EAS. The described immunocytochemical protocol facilitates prompt diagnosis exclusively through cytology samples.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This report emphasizes the potential for diagnosing EAS using cytological specimens, which is especially useful in cases where obtaining tissue samples proves challenging.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 10","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11498060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Four-Gene Autophagy-Related Prognostic Model Signature and Its Association With Immune Phenotype in Lung Squamous Cell Carcinoma 四基因自噬相关预后模型特征及其与肺鳞癌免疫表型的关系

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-10-23 DOI: 10.1002/cnr2.70000

Lumeng Luo, Jiaying Deng, Qiu Tang

Background

In the era of immunotherapy, there is a critical need for effective biomarkers to improve outcome prediction and guide treatment decisions for patients with lung squamous cell carcinoma (LUSC). We hypothesized that the immune contexture of LUSC may be influenced by tumor intrinsic events, such as autophagy.

Aims

We aimed to develop an autophagy-related risk signature and assess its predictive value for immune phenotype.

Methods and Results

Expression profiles of autophagy-related genes (ARGs) in LUSC samples were obtained from the TCGA and GEO databases. Survival analyses were conducted to identify survival-related ARGs and construct a risk signature using the Random Forest algorithm. Four ARGs (CFLAR, RGS19, PINK1, and CTSD) with the most significant prognostic value were selected to construct the risk signature. Patients in the high-risk group exhibited worse prognosis than those in the low-risk group (p < 0.0001 in TCGA; p < 0.01 in GEO) and the risk score was identified as an independent prognostic factor. We observed that the high-risk group displayed an immune-suppressive status and showed higher levels of infiltrating regulatory T cells and macrophages, which are associated with poorer outcomes. Additionally, the risk score exhibited a significantly positive correlation with the expression of PD-1 and CTLA4, as well as the estimate score and immune score.

Conclusion

This study provided an effective autophagy-related prognostic signature, which could also predict the immune phenotype.

背景：在免疫疗法时代，肺鳞状细胞癌（LUSC）患者亟需有效的生物标志物来改善预后预测并指导治疗决策。我们假设肺鳞状细胞癌的免疫环境可能受到肿瘤内在事件（如自噬）的影响：我们从TCGA和GEO数据库中获得了LUSC样本中自噬相关基因（ARGs）的表达谱。采用随机森林算法进行生存分析，以确定与生存相关的ARGs并构建风险特征。研究人员选择了预后价值最显著的四个ARG（CFLAR、RGS19、PINK1和CTSD）构建风险特征。与低风险组相比，高风险组患者的预后更差（P 结论：该研究提供了一种有效的自噬基因检测方法：本研究提供了一个有效的自噬相关预后特征，它还可以预测免疫表型。

{"title":"A Four-Gene Autophagy-Related Prognostic Model Signature and Its Association With Immune Phenotype in Lung Squamous Cell Carcinoma","authors":"Lumeng Luo, Jiaying Deng, Qiu Tang","doi":"10.1002/cnr2.70000","DOIUrl":"10.1002/cnr2.70000","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In the era of immunotherapy, there is a critical need for effective biomarkers to improve outcome prediction and guide treatment decisions for patients with lung squamous cell carcinoma (LUSC). We hypothesized that the immune contexture of LUSC may be influenced by tumor intrinsic events, such as autophagy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We aimed to develop an autophagy-related risk signature and assess its predictive value for immune phenotype.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Expression profiles of autophagy-related genes (ARGs) in LUSC samples were obtained from the TCGA and GEO databases. Survival analyses were conducted to identify survival-related ARGs and construct a risk signature using the Random Forest algorithm. Four ARGs (CFLAR, RGS19, PINK1, and CTSD) with the most significant prognostic value were selected to construct the risk signature. Patients in the high-risk group exhibited worse prognosis than those in the low-risk group (<i>p</i> < 0.0001 in TCGA; <i>p</i> < 0.01 in GEO) and the risk score was identified as an independent prognostic factor. We observed that the high-risk group displayed an immune-suppressive status and showed higher levels of infiltrating regulatory T cells and macrophages, which are associated with poorer outcomes. Additionally, the risk score exhibited a significantly positive correlation with the expression of PD-1 and CTLA4, as well as the estimate score and immune score.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study provided an effective autophagy-related prognostic signature, which could also predict the immune phenotype.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 10","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasma Profiling of Acute Myeloid Leukemia With Fever- and Infection-Related Complications During Chemotherapy-Induced Neutropenia 急性髓性白血病化疗期间发热和感染并发症的血浆谱分析

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-10-23 DOI: 10.1002/cnr2.70024

Iris C. Kreft, Annemarie van de Geer, Eva R. Smit, Carmen van der Zwaan, Floris P. J. van Alphen, Alexander B. Meijer, Erfan Nur, Arie J. Hoogendijk, Taco W. Kuijpers, Maartje van den Biggelaar

Background

Acute myeloid leukemia (AML) is a heterogenous and complex blood cancer requiring aggressive treatment. Early identification and prediction of the complications following treatment is vital for effective disease management.

Aims

We explored associations between plasma protein levels and fever- and infection-related complications in 26 AML patients during chemotherapy-induced neutropenia.

Material and Methods

Longitudinal plasma profiling was conducted using data-dependent mass spectrometry analysis.

Results

Mass spectrometry-based plasma profiling data correlated well with laboratory parameters, including C-reactive protein, and revealed a broader inflammation protein network associated with fever- and infection-related complications.

Discussion and Conclusion

These data indicate the potential of longitudinal plasma profiling in AML patients for identifying and predicting complications that may aid in improved disease monitoring and treatment.

背景：急性髓性白血病（AML）是一种需要积极治疗的异质性复杂血癌。目的：我们研究了 26 名急性髓性白血病患者在化疗引起的中性粒细胞减少症期间血浆蛋白水平与发热和感染相关并发症之间的关系：采用数据依赖性质谱分析法进行纵向血浆分析：基于质谱的血浆分析数据与实验室参数（包括C反应蛋白）相关性良好，并揭示了与发热和感染相关并发症有关的更广泛的炎症蛋白网络：这些数据表明，对急性髓细胞性白血病患者进行纵向血浆分析具有识别和预测并发症的潜力，有助于改善疾病监测和治疗。

{"title":"Plasma Profiling of Acute Myeloid Leukemia With Fever- and Infection-Related Complications During Chemotherapy-Induced Neutropenia","authors":"Iris C. Kreft, Annemarie van de Geer, Eva R. Smit, Carmen van der Zwaan, Floris P. J. van Alphen, Alexander B. Meijer, Erfan Nur, Arie J. Hoogendijk, Taco W. Kuijpers, Maartje van den Biggelaar","doi":"10.1002/cnr2.70024","DOIUrl":"10.1002/cnr2.70024","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute myeloid leukemia (AML) is a heterogenous and complex blood cancer requiring aggressive treatment. Early identification and prediction of the complications following treatment is vital for effective disease management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We explored associations between plasma protein levels and fever- and infection-related complications in 26 AML patients during chemotherapy-induced neutropenia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>Longitudinal plasma profiling was conducted using data-dependent mass spectrometry analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mass spectrometry-based plasma profiling data correlated well with laboratory parameters, including C-reactive protein, and revealed a broader inflammation protein network associated with fever- and infection-related complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion and Conclusion</h3>\u0000 \u0000 <p>These data indicate the potential of longitudinal plasma profiling in AML patients for identifying and predicting complications that may aid in improved disease monitoring and treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 10","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11498059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the Time Interval Between Symptoms Onset, Diagnosis, and Therapeutic Intervention in Lung Cancer: A Cross-Sectional Study in Southern Iran 评估肺癌发病、诊断和治疗干预之间的时间间隔：伊朗南部横断面研究

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-10-18 DOI: 10.1002/cnr2.70026

Alireza Salehi, Alireza Rezvani, Mohammad Javad Fallahi, Ghazal Gholamabbas, Maryam Moayedfar

Background and Aim

Delay in diagnosis and treatment of lung cancer is thought to be a major cause of its poor outcomes. We evaluated the delays within the presentation to the initiation of diagnostic and therapeutic interventions amongst lung cancer patients in Southern Iran.

Methods

This cross-sectional study was conducted from March 2019 to March 2021. The data collected through interview included socio-demographic, medical and clinical findings, and the time intervals needed to visit physician, refer to specialist, request diagnostic procedures, reach diagnosis of lung cancer, and hospitalization.

Results

Eighty-nine patients (58 males and 31 females) with a mean age of 61.01 ± 12.25 years were included. The median time of symptom presentation and first physician visit interval was 25 days. Sixty-five days were spent for requesting, performing, and evaluating the diagnostic procedures. The median interval between diagnosis and initiation of treatment was 16 days. Totally, it took an average of 122 days from the presentation to the definite diagnosis of lung cancer. Patient-, diagnosis-, and treatment-related delays were not significantly correlated with any of the demographic, socioeconomic, and clinical (disease stage, symptom) variables, as well as the diagnosis tool and the first physician who visited the patient (p > 0.05).

Conclusions

There was a significant delay but relatively similar to other countries in the diagnosis and treatment of lung cancer patients in Southern Iran. The largest portion of delay could be attributed to the raising clinical suspicion in the physicians, referral for diagnostic assessments, and the diagnosis process.

背景和目的肺癌诊断和治疗的延误被认为是导致肺癌治疗效果不佳的主要原因。我们评估了伊朗南部肺癌患者从发病到开始诊断和治疗干预的延迟情况。方法该横断面研究于 2019 年 3 月至 2021 年 3 月进行。通过访谈收集的数据包括社会人口学、医学和临床结果，以及从就诊、转诊至专科医生、申请诊断程序、确诊肺癌到住院治疗所需的时间间隔。结果共纳入 89 名患者（58 名男性和 31 名女性），平均年龄为 61.01±12.25 岁。出现症状和首次就诊间隔时间的中位数为 25 天。申请、执行和评估诊断程序的时间为 65 天。从诊断到开始治疗的中位时间间隔为 16 天。总之，从出现症状到确诊肺癌平均需要 122 天。与患者、诊断和治疗相关的延迟与任何人口统计学、社会经济学和临床（疾病分期、症状）变量以及诊断工具和首位就诊医生均无显著相关性（p > 0.05）。结论伊朗南部肺癌患者的诊断和治疗存在明显延迟，但与其他国家相对类似。延误的主要原因是医生的临床怀疑、转诊诊断评估和诊断过程。

{"title":"Evaluating the Time Interval Between Symptoms Onset, Diagnosis, and Therapeutic Intervention in Lung Cancer: A Cross-Sectional Study in Southern Iran","authors":"Alireza Salehi, Alireza Rezvani, Mohammad Javad Fallahi, Ghazal Gholamabbas, Maryam Moayedfar","doi":"10.1002/cnr2.70026","DOIUrl":"https://doi.org/10.1002/cnr2.70026","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Delay in diagnosis and treatment of lung cancer is thought to be a major cause of its poor outcomes. We evaluated the delays within the presentation to the initiation of diagnostic and therapeutic interventions amongst lung cancer patients in Southern Iran.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study was conducted from March 2019 to March 2021. The data collected through interview included socio-demographic, medical and clinical findings, and the time intervals needed to visit physician, refer to specialist, request diagnostic procedures, reach diagnosis of lung cancer, and hospitalization.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eighty-nine patients (58 males and 31 females) with a mean age of 61.01 ± 12.25 years were included. The median time of symptom presentation and first physician visit interval was 25 days. Sixty-five days were spent for requesting, performing, and evaluating the diagnostic procedures. The median interval between diagnosis and initiation of treatment was 16 days. Totally, it took an average of 122 days from the presentation to the definite diagnosis of lung cancer. Patient-, diagnosis-, and treatment-related delays were not significantly correlated with any of the demographic, socioeconomic, and clinical (disease stage, symptom) variables, as well as the diagnosis tool and the first physician who visited the patient (<i>p</i> > 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>There was a significant delay but relatively similar to other countries in the diagnosis and treatment of lung cancer patients in Southern Iran. The largest portion of delay could be attributed to the raising clinical suspicion in the physicians, referral for diagnostic assessments, and the diagnosis process.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 10","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validity and Reliability of the Amharic Version of EORTC QLQ-OG25 Among Esophagogastric Cancer Patients in Ethiopia 埃塞俄比亚食管胃癌患者阿姆哈拉语版 EORTC QLQ-OG25 的有效性和可靠性

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-10-18 DOI: 10.1002/cnr2.70035

Lidya Genene Abebe, Abigiya Wondimagegnehu, Eva Johanna Kantelhardt, Adamu Addissie

Background

Cancers of the stomach and esophagus are the fourth and sixth most common causes of cancer-related deaths worldwide, respectively. Although various tools have been developed to assess the quality of life of patients with esophagogastric cancer, EORTC QLQ-C30 and EORTC QLQ-OG25 are the most used all over the world. However, they have not been validated in an Ethiopian context. Therefore, this study aimed to evaluate the psychometric properties of EORTC QLQ-OG25 among Ethiopian patients with esophageal and gastric cancer.

Methods

EORTC QLQ-OG25 is a 25-item tool with 10 single items and six symptom scales: Eating restrictions, reflux, dysphagia, odynophagia, discomfort and pain, and anxiety. The tool was translated into Amharic according to the EORTC forward-backward translation protocol. To check its validity and reliability, a cross-sectional study among 158 patients was conducted from March to May 2020 at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. The psychometric properties of EORTC QLQ-C30 and EORTC QLQ-OG25 were assessed using multitrait scale analysis, known group validity, convergent validity, and divergent validity. Internal consistency was examined with Cronbach's alpha.

Result

Eighty-three (52.5%) of the participants were men; the median age was 50 years (IQR = 18 years). The overall item correlation alpha values ranged between 0.39 and 0.7. All item correlations within their scales were greater than 0.4. The correlation coefficients between all items and their own domain were greater than for other domains. The esophagogastric and core questionnaire correlation ranged from −0.65 to 0.62. The tool showed a significant difference between patients with good physical function and those with impaired physical function.

Conclusions

The findings suggest that the Amharic version of EORTC QLQ-OG25 is a valid and reliable tool among patients from Ethiopia with esophagus and gastric cancer. Therefore, we recommend that researchers and clinicians use the core tool together with the specific tool.

背景胃癌和食道癌分别是全球第四大和第六大癌症相关死亡原因。虽然已经开发了多种工具来评估食管胃癌患者的生活质量，但 EORTC QLQ-C30 和 EORTC QLQ-OG25 是全世界使用最多的工具。然而，它们尚未在埃塞俄比亚进行过验证。因此，本研究旨在评估 EORTC QLQ-OG25 在埃塞俄比亚食道癌和胃癌患者中的心理测量特性。方法 EORTC QLQ-OG25 是一个 25 个项目的工具，包括 10 个单项和 6 个症状量表：进食限制、反流、吞咽困难、吞咽困难、不适和疼痛以及焦虑。该工具根据 EORTC 前向-后向翻译协议翻译成阿姆哈拉语。为了检验该工具的有效性和可靠性，埃塞俄比亚亚的斯亚贝巴 Tikur Anbessa 专科医院于 2020 年 3 月至 5 月对 158 名患者进行了横断面研究。采用多特征量表分析、已知群体效度、收敛效度和发散效度评估了 EORTC QLQ-C30 和 EORTC QLQ-OG25 的心理测量特性。用 Cronbach's alpha 检验了内部一致性。结果 83 名参与者（52.5%）为男性，年龄中位数为 50 岁（IQR = 18 岁）。总体项目相关性α值介于 0.39 和 0.7 之间。量表内所有项目的相关系数均大于 0.4。所有项目与其自身领域的相关系数均大于其他领域。食管胃和核心问卷的相关系数在-0.65 到 0.62 之间。该工具显示，身体功能良好的患者与身体功能受损的患者之间存在明显差异。结论研究结果表明，在埃塞俄比亚的食道癌和胃癌患者中，阿姆哈拉语版 EORTC QLQ-OG25 是一种有效、可靠的工具。因此，我们建议研究人员和临床医生同时使用核心工具和特定工具。

{"title":"Validity and Reliability of the Amharic Version of EORTC QLQ-OG25 Among Esophagogastric Cancer Patients in Ethiopia","authors":"Lidya Genene Abebe, Abigiya Wondimagegnehu, Eva Johanna Kantelhardt, Adamu Addissie","doi":"10.1002/cnr2.70035","DOIUrl":"https://doi.org/10.1002/cnr2.70035","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancers of the stomach and esophagus are the fourth and sixth most common causes of cancer-related deaths worldwide, respectively. Although various tools have been developed to assess the quality of life of patients with esophagogastric cancer, EORTC QLQ-C30 and EORTC QLQ-OG25 are the most used all over the world. However, they have not been validated in an Ethiopian context. Therefore, this study aimed to evaluate the psychometric properties of EORTC QLQ-OG25 among Ethiopian patients with esophageal and gastric cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>EORTC QLQ-OG25 is a 25-item tool with 10 single items and six symptom scales: Eating restrictions, reflux, dysphagia, odynophagia, discomfort and pain, and anxiety. The tool was translated into Amharic according to the EORTC forward-backward translation protocol. To check its validity and reliability, a cross-sectional study among 158 patients was conducted from March to May 2020 at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. The psychometric properties of EORTC QLQ-C30 and EORTC QLQ-OG25 were assessed using multitrait scale analysis, known group validity, convergent validity, and divergent validity. Internal consistency was examined with Cronbach's alpha.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Result</h3>\u0000 \u0000 <p>Eighty-three (52.5%) of the participants were men; the median age was 50 years (IQR = 18 years). The overall item correlation alpha values ranged between 0.39 and 0.7. All item correlations within their scales were greater than 0.4. The correlation coefficients between all items and their own domain were greater than for other domains. The esophagogastric and core questionnaire correlation ranged from −0.65 to 0.62. The tool showed a significant difference between patients with good physical function and those with impaired physical function.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The findings suggest that the Amharic version of EORTC QLQ-OG25 is a valid and reliable tool among patients from Ethiopia with esophagus and gastric cancer. Therefore, we recommend that researchers and clinicians use the core tool together with the specific tool.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 10","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contrast-Enhanced Ultrasound-Based Radiomics for the Prediction of Axillary Lymph Nodes Status in Breast Cancer 基于对比增强超声的放射线组学用于预测乳腺癌腋窝淋巴结状态

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-10-18 DOI: 10.1002/cnr2.70011

Haimei Lun, Mohan Huang, Yihong Zhao, Jingyu Huang, Lingling Li, HoiYing Cheng, Yiki Leung, HongWai So, YuenChun Wong, ChakKwan Cheung, ChiWang So, Lawrence Wing Chi Chan, Qiao Hu

Background

Breast cancer is the leading cause of cancer-related deaths in the female population. Axillary lymph nodes (ALN) are a group of the most common metastatic sites of breast cancer. Timely assessment of ALN status is of paramount clinical importance for medical decision making.

Aims

To utilize contrast-enhanced ultrasound (CEUS)-based radiomics models for noninvasive pretreatment prediction of ALN status.

Methods and Results

Clinical data and pretreatment CEUS images of primary breast tumors were retrospectively studied to build radiomics signatures for pretreatment prediction of nodal status between May 2015 and July 2021. The cases were divided into the training cohorts and test cohorts in a 9:1 ratio. The mRMR approach and stepwise forward logistic regression technique were used for feature selection, followed by the multivariate logistic regression technique for building radiomics signatures in the training cohort. The confusion matrix and receiver operating characteristic (ROC) analysis were used for accessing the prediction efficacy of the radiomics models. The radiomics models, which consist of six features, achieved predictive accuracy with the area under the ROC curve (AUC) of 0.713 in the test set for predicting lymph node metastasis.

Conclusion

The CEUS-based radiomics is promising to be developed as a reliable noninvasive tool for predicting ALN status.

背景乳腺癌是女性因癌症死亡的主要原因。腋窝淋巴结（ALN）是乳腺癌最常见的转移部位之一。及时评估腋窝淋巴结的状态对临床医疗决策至关重要。目的利用基于对比增强超声（CEUS）的放射组学模型对腋窝淋巴结状态进行无创预处理预测。方法和结果回顾性研究了 2015 年 5 月至 2021 年 7 月期间原发性乳腺肿瘤的临床数据和预处理 CEUS 图像，以建立用于预处理预测结节状态的放射组学特征。病例按 9:1 的比例分为训练组和测试组。采用 mRMR 方法和逐步前向逻辑回归技术进行特征选择，然后采用多元逻辑回归技术在训练队列中建立放射组学特征。混淆矩阵和接收者操作特征（ROC）分析被用来评估放射组学模型的预测效果。由六个特征组成的放射组学模型在预测淋巴结转移的测试集中达到了预测准确性，ROC 曲线下面积（AUC）为 0.713。结论基于 CEUS 的放射组学有望发展成为预测 ALN 状态的可靠无创工具。

{"title":"Contrast-Enhanced Ultrasound-Based Radiomics for the Prediction of Axillary Lymph Nodes Status in Breast Cancer","authors":"Haimei Lun, Mohan Huang, Yihong Zhao, Jingyu Huang, Lingling Li, HoiYing Cheng, Yiki Leung, HongWai So, YuenChun Wong, ChakKwan Cheung, ChiWang So, Lawrence Wing Chi Chan, Qiao Hu","doi":"10.1002/cnr2.70011","DOIUrl":"https://doi.org/10.1002/cnr2.70011","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer is the leading cause of cancer-related deaths in the female population. Axillary lymph nodes (ALN) are a group of the most common metastatic sites of breast cancer. Timely assessment of ALN status is of paramount clinical importance for medical decision making.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To utilize contrast-enhanced ultrasound (CEUS)-based radiomics models for noninvasive pretreatment prediction of ALN status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Clinical data and pretreatment CEUS images of primary breast tumors were retrospectively studied to build radiomics signatures for pretreatment prediction of nodal status between May 2015 and July 2021. The cases were divided into the training cohorts and test cohorts in a 9:1 ratio. The mRMR approach and stepwise forward logistic regression technique were used for feature selection, followed by the multivariate logistic regression technique for building radiomics signatures in the training cohort. The confusion matrix and receiver operating characteristic (ROC) analysis were used for accessing the prediction efficacy of the radiomics models. The radiomics models, which consist of six features, achieved predictive accuracy with the area under the ROC curve (AUC) of 0.713 in the test set for predicting lymph node metastasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The CEUS-based radiomics is promising to be developed as a reliable noninvasive tool for predicting ALN status.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 10","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanism of Drug Resistance to First-Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas 神经母细胞瘤中 TXNDC17 介导的一线化疗药物耐药机制

IF 1.5 Q4 ONCOLOGY

Cancer reports

Pub Date : 2024-10-16 DOI: 10.1002/cnr2.70033

Chenggong Zeng, Zhuoran Li, Zhiqing Wei, Tingting Chen, Juan Wang, Junting Huang, Feifei Sun, Jia Zhu, Suying Lu, Zijun Zhen

Background

The prognosis of high-risk neuroblastomas (NB) that are resistant to first-line induction chemotherapy is relatively poor. This study explored the mechanism of resistance to first-line chemotherapeutics mediated by TXNDC17 and its potential solutions in NB.

Methods

The genetic and clinical data of patients with NB were obtained from the Therapeutically Applicable Research to Generate Effective Treatments dataset. TXNDC17 and BECN1 expressions in NB cells were up- and downregulated by transfection with plasmids and shRNA, respectively. Autophagy-related proteins were detected by western blot. Cell viability was determined using cell proliferation and toxicity experiments. Apoptotic cells were detected using flow cytometry.

Results

Overall, 1076 pediatric and adolescent patients with NB were enrolled in this study. The 10-year overall survival (OS) rates and event-free survival (EFS) rates for the patients with a mutation of BECN1 were 37.4 ± 9.1% and 34.5 ± 8.8%, respectively. For patients with a mutation of TXNDC17, the 10-year OS and EFS were 41.4 ± 5.9% and 24.3 ± 5.1%, respectively, which were significantly lower than those in the unaltered group. The overexpression of BECN1 and TXNDC17 reduced NB sensitivity to cisplatin (DDP), etoposide (VP16), and cyclophosphamide (CTX). Autophagy mediated by BECN1 was regulated by TXNDC17, and this process was involved in the resistance to DDP, VP16, and CTX in NB. Suberoylanilide hydroxamic acid (SAHA) can enhance the sensitivity and apoptosis of NB cells to chemotherapeutics by inhibiting TXNDC17, ultimately decreasing autophagy-mediated chemoresistance.

Conclusions

Acquired resistance to first-line chemotherapeutics was associated with autophagy mediated by BECN1 and regulated by TXNDC17, which can be reversed by SAHA.

背景对一线诱导化疗耐药的高危神经母细胞瘤（NB）预后相对较差。本研究探讨了 TXNDC17 介导的一线化疗耐药机制及其在 NB 中的潜在解决方案。方法 NB患者的基因和临床数据来自 "产生有效治疗的治疗性研究 "数据集。通过转染质粒和 shRNA，分别上调和下调 TXNDC17 和 BECN1 在 NB 细胞中的表达。自噬相关蛋白通过蛋白印迹进行检测。通过细胞增殖和毒性实验确定细胞活力。采用流式细胞术检测凋亡细胞。结果共有1076名儿童和青少年NB患者参与了这项研究。BECN1基因突变患者的10年总生存率（OS）和无事件生存率（EFS）分别为37.4±9.1%和34.5±8.8%。TXNDC17突变患者的10年OS和EFS分别为（41.4±5.9）%和（24.3±5.1）%，明显低于未突变组。BECN1和TXNDC17的过表达降低了NB对顺铂（DDP）、依托泊苷（VP16）和环磷酰胺（CTX）的敏感性。BECN1介导的自噬受TXNDC17调节，这一过程参与了NB对DDP、VP16和CTX的抗性。辛酰羟肟酸（SAHA）可通过抑制 TXNDC17 提高 NB 细胞对化疗药物的敏感性和凋亡率，最终降低自噬介导的化疗耐药性。结论对一线化疗药物的获得性耐药性与 BECN1 介导并受 TXNDC17 调节的自噬有关，而 SAHA 可以逆转自噬。

{"title":"Mechanism of Drug Resistance to First-Line Chemotherapeutics Mediated by TXNDC17 in Neuroblastomas","authors":"Chenggong Zeng, Zhuoran Li, Zhiqing Wei, Tingting Chen, Juan Wang, Junting Huang, Feifei Sun, Jia Zhu, Suying Lu, Zijun Zhen","doi":"10.1002/cnr2.70033","DOIUrl":"https://doi.org/10.1002/cnr2.70033","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The prognosis of high-risk neuroblastomas (NB) that are resistant to first-line induction chemotherapy is relatively poor. This study explored the mechanism of resistance to first-line chemotherapeutics mediated by TXNDC17 and its potential solutions in NB.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The genetic and clinical data of patients with NB were obtained from the Therapeutically Applicable Research to Generate Effective Treatments dataset. TXNDC17 and BECN1 expressions in NB cells were up- and downregulated by transfection with plasmids and shRNA, respectively. Autophagy-related proteins were detected by western blot. Cell viability was determined using cell proliferation and toxicity experiments. Apoptotic cells were detected using flow cytometry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 1076 pediatric and adolescent patients with NB were enrolled in this study. The 10-year overall survival (OS) rates and event-free survival (EFS) rates for the patients with a mutation of BECN1 were 37.4 ± 9.1% and 34.5 ± 8.8%, respectively. For patients with a mutation of TXNDC17, the 10-year OS and EFS were 41.4 ± 5.9% and 24.3 ± 5.1%, respectively, which were significantly lower than those in the unaltered group. The overexpression of BECN1 and TXNDC17 reduced NB sensitivity to cisplatin (DDP), etoposide (VP16), and cyclophosphamide (CTX). Autophagy mediated by BECN1 was regulated by TXNDC17, and this process was involved in the resistance to DDP, VP16, and CTX in NB. Suberoylanilide hydroxamic acid (SAHA) can enhance the sensitivity and apoptosis of NB cells to chemotherapeutics by inhibiting TXNDC17, ultimately decreasing autophagy-mediated chemoresistance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Acquired resistance to first-line chemotherapeutics was associated with autophagy mediated by BECN1 and regulated by TXNDC17, which can be reversed by SAHA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"7 10","pages":""},"PeriodicalIF":1.5,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0